<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542254</url>
  </required_header>
  <id_info>
    <org_study_id>RPL554-009-2015</org_study_id>
    <secondary_id>2015-002536-41</secondary_id>
    <nct_id>NCT02542254</nct_id>
  </id_info>
  <brief_title>The Effects of RPL554 on Top of Standard COPD Reliever Medications</brief_title>
  <official_title>A Phase II, Randomised, Double Blind, Placebo Controlled, Six Way Crossover Study to Assess the Bronchodilator Effect of RPL554 Administered on Top of Salbutamol and Ipratropium in Patients With COPD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verona Pharma plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verona Pharma plc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of RPL554 to standard reliever medications for chronic
      obstructive pulmonary disorder (COPD). All patients will receive the same six treatments in a
      randomised sequence:

        1. salbutamol,

        2. ipratropium,

        3. salbutamol + RPL554,

        4. ipratropium + RPL554,

        5. RPL554

        6. Placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate if RPL554 has an additive bronchodilator effect
      when administered in combination with standard of care bronchodilators in patients with
      COPD.This study investigates the pharmacodynamic effect of RPL554 using spirometry and whole
      body plethysmography compared to placebo, when administered in addition to a beta2 agonist
      (salbutamol), a muscarinic antagonist (ipratropium) or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>8 hour spirometry</measure>
    <time_frame>8 hours</time_frame>
    <description>Forced expired volume in one second (FEV1) over 8 hours post-dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>12 hour spirometry</measure>
    <time_frame>12 hours</time_frame>
    <description>FEV1 over 4, 6 and 12 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole body plethysmography</measure>
    <time_frame>4 hours</time_frame>
    <description>Functional residual capacity, residual volume, total lung capacity, specific airway conductance, specific airway resistance at 1 and 4 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>12 hours</time_frame>
    <description>AUC for RPL554 plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>12 hours</time_frame>
    <description>Cmax for RPL554 plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>12 hours</time_frame>
    <description>Tmax for RPL554 plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 94 days</time_frame>
    <description>Continuous measurement of adverse events throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety laboratory tests</measure>
    <time_frame>Up to 94 days</time_frame>
    <description>Laboratory safety tests at screening, before each treatment and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>Up to 94 days</time_frame>
    <description>12 lead ECG at screening, before and up to 12 hours after each treatment and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Up to 94 days</time_frame>
    <description>Blood pressure and pulse rate at screening, before and up to 12 hours after each treatment and end of study</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Salbutamol alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 micrograms salbutamol, ipratropium matched placebo and RPL554 matched placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salbutamol and RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 micrograms salbutamol, ipratropium matched placebo and 6 mg RPL554</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ipratropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salbutamol matched placebo, 40 micrograms ipratropium and RPL554 matched placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ipratropium and RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salbutamol matched placebo, 40 micrograms ipratropium and 6 mg RPL554</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salbutamol matched placebo, ipratropium matched placebo and 6 mg RPL554</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Salbutamol matched placebo, ipratropium matched placebo and RPL554 matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <description>200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)</description>
    <arm_group_label>Salbutamol alone</arm_group_label>
    <arm_group_label>Salbutamol and RPL554</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium</intervention_name>
    <description>40 micrograms ipratropium administered using a pMDI</description>
    <arm_group_label>Ipratropium</arm_group_label>
    <arm_group_label>Ipratropium and RPL554</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPL554</intervention_name>
    <description>6 mg RPL554 administered using a nebuliser</description>
    <arm_group_label>Salbutamol and RPL554</arm_group_label>
    <arm_group_label>Ipratropium and RPL554</arm_group_label>
    <arm_group_label>RPL554</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol matched placebo</intervention_name>
    <description>Placebo pMDI</description>
    <arm_group_label>Ipratropium</arm_group_label>
    <arm_group_label>Ipratropium and RPL554</arm_group_label>
    <arm_group_label>RPL554</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium matched placebo</intervention_name>
    <description>Placebo pMDI</description>
    <arm_group_label>Salbutamol alone</arm_group_label>
    <arm_group_label>Salbutamol and RPL554</arm_group_label>
    <arm_group_label>RPL554</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPL554 matched placebo</intervention_name>
    <description>Nebulised placebo</description>
    <arm_group_label>Salbutamol alone</arm_group_label>
    <arm_group_label>Ipratropium</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide informed consent

          -  Males not donating sperm and using adequate contraception or females who are
             surgically sterile or postmenopausal

          -  12-lead ECG showing:Heart rate 45 to 90 bpm, QTcF≤450 msec, QRS ≤120 msec, PR interval
             ≤220 msec, no clinically significant abnormality

          -  Capable of complying with all study restrictions and procedures including ability to
             use the study nebuliser correctly.

          -  BMI 18 to 33 kg/m2 with a minimum weight of 45 kg.

          -  COPD diagnosis for at least 1 year and clinically stable COPD in previous 4 weeks

          -  Demonstrates reversibility to bronchodilator (two puffs of salbutamol followed by two
             puffs of ipratropium) via spirometry:

               -  Post-bronchodilator FEV1/forced vital capacity (FVC) ratio of ≤0.70

               -  Post-bronchodilator FEV1 ≥40 % and ≤80% of predicted normal

               -  ≥150 mL increase from pre-bronchodilator FEV1

          -  Chest X-ray showing no abnormalities

          -  Meet the concomitant medication restrictions and be expected to do so for the rest of
             the study.

          -  Smoking history of ≥10 pack years.

          -  Capable of withdrawing from long acting bronchodilators throughout the study and short
             acting bronchodilators for 8 hours prior to study treatment.

        Exclusion Criteria:

          -  History of life-threatening COPD including Intensive Care Unit admission and/or
             requiring intubation.

          -  COPD exacerbation requiring oral steroids in the previous 3 months

          -  History of one or more hospitalisations for COPD in the previous 12 months

          -  Respiratory tract infection (both upper and lower) treated with antibiotics in
             previous 12 weeks

          -  Evidence of cor pulmonale or clinically significant pulmonary hypertension.

          -  Other respiratory disorders

          -  Previous lung resection or lung reduction surgery.

          -  Oral therapies for COPD in the previous 3 months and throughout the study.

          -  Drug or alcohol abuse in the past 3 years

          -  Received an experimental drug within 3 months or five half lives, whichever is longer.

          -  Prior exposure to RPL554

          -  Patients with a history of chronic uncontrolled disease that the Investigator believes
             are clinically significant.

          -  Documented cardiovascular disease in last 3 months

          -  Major surgery, (requiring general anaesthesia) in the previous 6 weeks, or will not
             have fully recovered from surgery, or planned surgery through the end of the study.

          -  History of malignancy of any organ system within 5 years with the exception of
             localised skin cancers (basal or squamous cell)

          -  Clinically significant abnormal values for safety laboratory tests

          -  A disclosed history, or one known to the Investigator, of significant non compliance
             in previous investigational studies or with prescribed medications.

          -  Requires oxygen therapy, even on an occasional basis.

          -  Inability to adequately perform whole body plethysmography.

          -  Any other reason that the Investigator considers makes the subject unsuitable to
             participate.

          -  Patients with known hypersensitivity to atropine or its derivatives, or to ipratropium
             bromide, salbutamol or RPL554 or their excipients/components.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Singh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicines Evaluation Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>September 8, 2016</last_update_submitted>
  <last_update_submitted_qc>September 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

